compound glp 1 news FDA proposes a new GLP-1 compounding crackdown Compounded GLP-1
Description
Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist currently licensed in the UK for type 2 diabetes only
Sandoval et al., 2008
Similarly, the trend remained unchanged in the stratified analysis according to the status of comorbidities, including MASH, LC, heart failure, T2D and CKD
It is not uncommon to see weight loss as early as one week into treatment, but speeds will vary from person to person
Importantly, these medications carry a boxed warning for risk of thyroid C-cell tumors and are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
